Sugammadex Mylan | European Medicines Agency (EMA)

[ad_1]

Overview

Sugammadex Mylan is a medicine used to reverse the effect of the muscle relaxants rocuronium and vecuronium. Muscle relaxants are medicines used during some types of operation to make the muscles relax, including the muscles that help the patient to breathe. Muscle relaxants make it easier for the surgeon to do the operation. Sugammadex Mylan is used to speed up the recovery from the muscle relaxant, usually at the end of the operation.

Sugammadex Mylan can be used in adults who have received rocuronium and vecuronium, and in children aged 2 years or older who have received rocuronium.

Sugammadex Mylan contains the active substance sugammadex and is a ‘generic medicine’. This means that Sugammadex Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Bridion.

Sugammadex Mylan can only be obtained with a prescription. It is given by or under the supervision of an anaesthetist (a doctor specialised in anaesthesia). Sugammadex Mylan is given into a vein as a single ‘bolus’ injection (given all at once). The dose depends on the patient’s age and body weight and on how much the muscle relaxant is affecting the muscles.

Sugammadex Mylan is not recommended for use in children and adolescents for recovery after vecuronium, or for rapid recovery after any muscle relaxant.

For more information about using Sugammadex Mylan, see the package leaflet or contact your doctor or pharmacist.

The active substance in Sugammadex Mylan, sugammadex, is a ‘selective relaxant binding agent’. This means that it attaches to the muscle relaxants rocuronium and vecuronium forming a ‘complex’ that inactivates the muscle relaxants and stops them having an effect. As a result, the effect of blockade of the muscles due to rocuronium and vecuronium on the muscles is reversed, and the muscles begin to work normally again, including the muscles that help the patient to breathe.

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Bridion, and do not need to be repeated for Sugammadex Mylan.

As for every medicine, the company provided studies on the quality of Sugammadex Mylan. There was no need for ‘bioequivalence’ studies to investigate whether Sugammadex Mylan is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Sugammadex Mylan is given by injection into a vein, so the active substance is delivered straight into the bloodstream.

Because Sugammadex Mylan is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The European Medicines Agency concluded that, in accordance with EU requirements, Sugammadex Mylan has been shown to be comparable to Bridion. Therefore, the Agency’s view was that, as for Bridion, the benefits of Sugammadex Mylan outweigh the identified risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sugammadex Mylan have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sugammadex Mylan are continuously monitored. Suspected side effects reported with Sugammadex Mylan are carefully evaluated and any necessary action taken to protect patients.

Sugammadex Mylan received a marketing authorisation valid throughout the EU on 15 November 2021.

English (EN)
(143.16 KB – PDF)

First published: 22/11/2021

View

English (EN)
(82.72 KB – PDF)

First published: 22/11/2021

View

Product information

English (EN)
(425.66 KB – PDF)

First published: 22/11/2021Last updated: 12/03/2025

View

Latest procedure affecting product information:
VR/0000253871

12/03/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(15.89 KB – PDF)

First published: 22/11/2021

View

Product details

Name of medicine: Sugammadex Mylan
Active substance: sugammadex sodium
International non-proprietary name (INN) or common name: sugammadex
Therapeutic area (MeSH): Neuromuscular Blockade
Anatomical therapeutic chemical (ATC) code: V03AB35

Pharmacotherapeutic group

All other therapeutic products

Therapeutic indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

More information on Sugammadex Mylan

English (EN)
(66.45 KB – PDF)

First published: 09/07/2007Last updated: 07/12/2012

View

[ad_2]

Source link

Subscribe now

To access premium content

Hong Kong could be the centre of the next NFT boom

Graphics Lifting For CropBytes Crypto Farming Game

Immortals and Fetch.ai Form Landmark Crypto Partnership

The Metaverse Creation, Ronin Wallet is Live & More News

What is Binamon? Ready For Launch On August 28

Binapet Review: Breeding BSC Play-to-Earn Game

The Galaxy of Lemuria Review – Play To Earn MMORPG

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

BLAST Premier 2022 – Betting Tips and Schedule

Is Overwatch League Getting Outsourced A Good Thing?

Genesis Worlds Interview With CEO Jason Cassidy

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead